Abhijit Mazumdar, Ph.D.
Department of Clinical Cancer Prevention, Division of Cancer Prevention and Population Sciences
About Dr. Abhijit Mazumdar
The goal of the proposed research is to investigate the effective preventive therapies for ER negative breast cancer using high throughput screening of siRNA kinase library when combined with rexinoid. I have the expertise and motivation to successfully carry out the proposed research project. I have a broad research background in developing novel molecular-targets for cancer prevention and therapeutics including laboratory-based identification and validation of targets. I have been extensively trained in cell and molecular cancer biology and would like to utilize my expertise in cancer prevention and in targeted therapy. In summary I will be interested in the projects in cancer prevention involving kinases activated in cancer and their inhibition in combination with rexinoids.
Read More
Present Title & Affiliation
Primary Appointment
Associate Professor, Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1998 | Jadavpur University, Calcutta, IN, Biochemistry, Ph.D |
| 1991 | University of Calcutta, Calcutta, IN, Biochemistry, M.S |
| 1988 | University of Calcutta, Calcutta, IN, Chemistry, BS |
Postgraduate Training
| 2000-2003 | Postdoctoral Fellow, Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 1999-2000 | Postdoctoral Fellow, Cell Growth Regulation, Experimental Therapeutics, Division of Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 1997-1999 | Postdoctoral Fellow, CCIPE (CNRS), Montpellier |
| 1992-1996 | Research Fellowship, Indian Institute of Chemical Biology, Calcutta |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, 2009 - 2020
Research Associate, Breast Center, Baylor College of Medicine, Houston, TX, 2008 - 2009
Instructor, Head and Neck Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 2004 - 2007
Other Professional Positions
Member, Institutional IACUC committee, Houston, TX, 2020 - Present
Senior Scientist, Dr. Reddy's Laboratories, Hyderabad, 2003 - 2004
Member, AACR, Houston, TX, 2001 - Present
Honors & Awards
| 1999 - 2003 | Postdoctoral Fellow, MD Anderson Cancer Center, Department of Molecular Cellular Oncology |
| 1998 - 1999 | Postdoctoral Fellow, ARC, Association for Research on Cancer-France |
| 1997 - 1999 | Postdoctoral Fellow, FRM, Foundation for Medical Research-France |
| 1992 - 1996 | Research Fellowship, CSIR, Indian Institute of Chemical Biology, Calcutta, India |
| 1992 - 1996 | Senior Research Fellow, SRF, Indian Institute of Chemical Biology, Calcutta, India |
| 1992 | Qualified National Eligibility Test (CSIR-NET) Conducted by UGC-CSIR, Government of India |
| 1992 | Qualified Graduate Aptitude Test in Engineering (GATE), Department of Education-Government of India |
Professional Memberships
Grant & Contract Support
| Date: | 2025 - 2030 |
| Title: | Repurposing of eliglustat for prevention of triple-negative breast cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | FP00025223 |
| Date: | 2025 - 2029 |
| Title: | Repurposing Existing Small Molecule Inhibitors of Glucosylceramide Synthase for Prevention of ER- Breast Cancer |
| Funding Source: | US Department of Defense |
| Role: | Co-PI |
| ID: | FP00026785 |
| Date: | 2025 - 2028 |
| Title: | Inhibition of androgen receptor signaling for prevention and interception of hormone receptor negative breast cancers |
| Funding Source: | CPRIT |
| Role: | Co-I |
| ID: | FP00026208 |
| Date: | 2025 - 2028 |
| Title: | Inhibition of androgen receptor signaling for prevention and interception of hormone receptor negative breast cancers |
| Funding Source: | Cancer Prevention Research Inst of TX (CPRIT) |
| Role: | Co-I |
| ID: | FP00026208 |
| Date: | 2025 - 2030 |
| Title: | Chimeric RNA driven neopeptide vaccine for prevention of breast cancer in germline BRCA1/2 carriers |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | FP00020013_Res1 |
| Date: | 2024 - 2026 |
| Title: | Preventing ER-Negative and Triple-Negative Breast Cancer with Immunomodulatory Drugs |
| Funding Source: | Breast Cancer Research Foundation |
| Role: | Co-PI |
| ID: | BCRF-24-020 |
| Date: | 2023 - 2027 |
| Title: | Moving PARP Inhibitors Beyond BRCAness as Immune Modulating Agents for TNBC Prevention |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| ID: | BC220706 |
| Date: | 2022 - 2024 |
| Title: | Preventing BRCA1-Deficient Breast Cancer by Combining Immune and Targeted Therapies |
| Funding Source: | Breast Cancer Research Foundation |
| Role: | Co-I |
| ID: | BCRF 22-23 |
| Date: | 2022 - 2026 |
| Title: | Preclinical PREVENT Cancer Program: Targeting the PARP pathways for the Prevention of Triple-Negative Breast Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 75N91019D00021/75N91022F00001 |
| Date: | 2021 - 2022 |
| Title: | Targeting SOX9 Upstream Activators for the Treatment of Metastatic Breast Cancer |
| Funding Source: | Breast Cancer Research Foundation |
| Role: | Co-I |
| Date: | 2020 - 2019 |
| Title: | Targeting SOX9-Activating Proteins for the Prevention and Treatment of Breast Cancer Metastasis |
| Funding Source: | Breast Cancer Research Foundation |
| Role: | Co-I |
| Date: | 2019 - 2023 |
| Title: | Preclinical PREVENT Cancer Program: Cancer Prevention by Vaccination against Induced Antigen |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | TORF-2019-E07 |
| Date: | 2018 - 2021 |
| Title: | Targeting a Master Regulator of Triple-negative Breast Cancer Metastasis |
| Funding Source: | Breast Cancer Research Foundation |
| Role: | Co-I |
| Date: | 2018 - 2019 |
| Title: | Targeting SOX9 to Prevent Triple-negative Breast Cancer Metastasis, Breast Cancer Research Foundation |
| Funding Source: | Breast Cancer Research Foundation |
| Role: | Co-I |
| Date: | 2018 - 2023 |
| Title: | Preclinical PREVENT Cancer Program: Targeting the RXR Pathway for the Prevention of Triple Negative Breast Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | HHSN261201500018I / HHSN26100008 |
| Date: | 2017 - 2021 |
| Title: | Preclinical PREVENT Cancer Program: Targeting the mTOR Pathway for Prevention of Breast Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2016 - 2020 |
| Title: | Preclinical PREVENT Cancer Award: Cancer Prevention by alpha-Enolase Vaccination |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2015 - 2016 |
| Title: | Targeting the MELK protein for the treatment of triple negative breast cancer |
| Funding Source: | Susan G. Komen Breast Cancer Foundation |
| Role: | Collaborator |
| Date: | 2015 - 2016 |
| Title: | DAPK-1 a novel target for the treatment of triple-negative breast cancer |
| Funding Source: | MD Anderson |
| Role: | Collaborator |
| ID: | BCRF DAPK-1 |
| Date: | 2015 - 2015 |
| Title: | NO TITLE PROVIDED |
| Funding Source: | BCRF DAPK-1 |
| Role: | Collaborator |
| Date: | 2014 - 2015 |
| Title: | Targeting DAPK-1 for the treatment of p53-mutant Breast Cancer |
| Funding Source: | MD Anderson |
| Role: | Collaborator |
| ID: | BCRF DAPK-1 project 00002547 |
| Date: | 2012 - 2013 |
| Title: | Targeting MAP3Ks for Treatment of Triple-Negative Breast Cancers |
| Funding Source: | MD Anderson |
| Role: | Collaborator |
| ID: | BCRF MAP3K project 00000014 |
| Date: | 2012 - 2013 |
| Title: | Targeting MAP3Ks for the Treatment of Triple-Negative Breast Cancer |
| Funding Source: | Breast Cancer Research Foundation |
| Role: | Collaborator |
| ID: | BCRF |
| Date: | 2012 - 2015 |
| Title: | Targeting ACP1 for the Treatment of ER-negative Breast Cancer Komen SAB |
| Funding Source: | Susan G. Komen Breast Cancer Foundation |
| Role: | Collaborator |
| Date: | 2012 - 2015 |
| Title: | Identification of Phosphatases for the Treatment of ER-Negative Breast Cancer |
| Funding Source: | Susan G. Komen Breast Cancer Foundation |
| Role: | Collaborator |
| ID: | Komen SAB project 00989626 |
| Date: | 2009 - 2010 |
| Title: | Targeting Phosphatases for the Treatment of ER-negative Breast Cancer |
| Funding Source: | Susan G. Komen Breast Cancer Foundation |
| Role: | Collaborator |
| ID: | Komen SAB |
| Date: | 2009 - 2010 |
| Title: | Combining Cancer Prevention Drugs to Eliminate Cancer Stem Cells and Prevent Breast Cancer |
| Funding Source: | Breast Cancer Research Fund |
| Role: | Collaborator |
| ID: | BCRF |
| Date: | 2005 |
| Title: | Investigating Headpin, a potential anti-invasive and anti-Angiogenic candidate |
| Funding Source: | Head and Neck Spore |
| Role: | PI |
| Date: | 2004 |
| Title: | Investigating Headpin, a potential anti-invasive and anti-Angiogenic candidate |
| Funding Source: | Head & Neck Spore |
| Role: | PI |
Selected Publications
Peer-Reviewed Articles
- Tahaney WM, Lanier A, Qian J, Moyer CL, Nguyen N, Ma Y, Hill J, Powell RT, Stephan CC, Davies PJA, Mazumdar A, Brown PH. Inhibition of GPX4 induces the death of p53-mutant triple-negative breast cancer cells. Breast Cancer Res Treat 215(2):49, 2026. e-Pub 2026. PMID: 41493644.
- Moyer CL, Hill JL, Coleman D, Lanier A, Ma Y, Liu X, Kawedia J, Contreras A, Vuligonda V, Savage MI, Sanders ME, Mohammed A, Sei S, Brown PH, Mazumdar A. Targeting the RXR Pathway for the Prevention of Triple Negative Breast Cancer. Cancer Prev Res (Phila), 2025. e-Pub 2025. PMID: 41134141.
- Moyer CL, Lanier A, Qian J, Coleman D, Hill J, Vuligonda V, Sanders ME, Mazumdar A, Brown PH. IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy. Clin Cancer Res 30(11):2558-2570, 2024. e-Pub 2024. PMID: 38578278.
- Qian J, Ma Y, Tahaney WM, Moyer CL, Lanier A, Hill J, Coleman D, Koupaei N, Hilsenbeck SG, Savage MI, Page BDG, Mazumdar A, Brown PH. Correction: The novel phosphatase NUDT5 is a critical regulator of triple-negative breast cancer growth. Breast Cancer Res 26(1):53, 2024. e-Pub 2024. PMID: 38532428.
- Qian J, Ma Y, Tahaney WM, Moyer CL, Lanier A, Hill J, Coleman D, Koupaei N, Hilsenbeck SG, Savage MI, Page BDG, Mazumdar A, Brown PH. The novel phosphatase NUDT5 is a critical regulator of triple-negative breast cancer growth. Breast Cancer Res 26(1):23, 2024. e-Pub 2024. PMID: 38317231.
- Mazumdar A, Tahaney WM, Hill JL, Zhang Y, Ramachandran S, Kawedia J, Qian J, Contreras A, Savage MI, Vornik LA, Sei S, Mohammed A, Brown PH. Targeting the mTOR Pathway for the Prevention of ER-negative Breast Cancer. Cancer Prev Res (Phila) 15(12):791-802, 2022. e-Pub 2022. PMID: 35981902.
- Ma Y, Shepherd J, Zhao D, Bollu LR, Tahaney WM, Hill J, Zhang Y, Mazumdar A, Brown PH. SOX9 is Essential for Triple-Negative Breast Cancer Cell Survival and Metastasis. Mol Cancer Res. e-Pub 2020. PMID: 32661114.
- Tan X, Banerjee P, Pham EA, Rutaganira FUN, Basu K, Bota-Rabassedas N, Guo HF, Grzeskowiak CL, Liu X, Yu J, Shi L, Peng DH, Rodriguez BL, Zhang J, Zheng V, Duose DY, Solis LM, Mino B, Raso MG, Behrens C, Wistuba II, Scott KL, Smith M, Nguyen K, Lam G, Choong I, Mazumdar A, Hill JL, Gibbons DL, Brown PH, Russell WK, Shokat K, Creighton CJ, Glenn JS, Kurie JM. PI4KIIIβ is a therapeutic target in chromosome 1q-amplified lung adenocarcinoma. Sci Transl Med 12(527), 2020. e-Pub 2020. PMID: 31969487.
- Bollu LR, Shepherd J, Zhao D, Ma Y, Tahaney W, Speers C, Mazumdar A, Mills GB, Brown PH. Mutant P53 induces MELK expression by release of wild-type P53-dependent suppression of FOXM1. NPJ Breast Cancer 6:2, 2020. e-Pub 2020. PMID: 31909186.
- Mazumdar A, Tahaney WM, Reddy Bollu L, Poage G, Hill J, Zhang Y, Mills GB, Brown PH. The phosphatase PPM1A inhibits triple negative breast cancer growth by blocking cell cycle progression. NPJ Breast Cancer 5:22, 2019. e-Pub 2019. PMID: 31372497.
- Bollu LR, Mazumdar A, Savage MI, Brown PH. Molecular Pathways: Targeting Protein Tyrosine Phosphatases in Cancer. Clin Cancer Res 23(9):2136-2142, 2017. e-Pub 2017. PMID: 28087641.
- Mazumdar A, Poage GM, Shepherd J, Tsimelzon A, Hartman ZC, Den Hollander P, Hill J, Zhang Y, Chang J, Hilsenbeck SG, Fuqua S, Kent Osborne C, Mills GB, Brown PH. Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion. Breast Cancer Res Treat 158(3):441-54, 2016. e-Pub 2016. PMID: 27393618.
- Malorni L, Giuliano M, Migliaccio I, Wang T, Creighton CJ, Lupien M, Fu X, Hilsenbeck SG, Healy N, De Angelis C, Mazumdar A, Trivedi MV, Massarweh S, Gutierrez C, De Placido S, Jeselsohn R, Brown M, Brown PH, Osborne CK, Schiff R. Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. Mol Cancer Res 14(5):470-81, 2016. e-Pub 2016. PMID: 26965145.
- den Hollander P, Rawls K, Tsimelzon A, Shepherd J, Mazumdar A, Hill J, Fuqua SA, Chang JC, Osborne CK, Hilsenbeck SG, Mills GB, Brown PH. Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival. Cancer Res 76(7):1942-53, 2016. e-Pub 2016. PMID: 26921331.
- Shepherd JH, Uray IP, Mazumdar A, Tsimelzon A, Savage M, Hilsenbeck SG, Brown PH. The SOX11 transcription factor is a critical regulator of basal-like breast cancer growth, invasion, and basal-like gene expression. Oncotarget 7(11):13106-21, 2016. e-Pub 2016. PMID: 26894864.
- Rajput S, Puvvada N, Kumar BN, Sarkar S, Konar S, Bharti R, Dey G, Mazumdar A, Pathak A, Fisher PB, Mandal M. Overcoming Akt Induced Therapeutic Resistance in Breast Cancer through siRNA and Thymoquinone Encapsulated Multilamellar Gold Niosomes. Mol Pharm 12(12):4214-25, 2015. e-Pub 2015. PMID: 26505213.
- Zhao J, Zhao D, Poage GM, Mazumdar A, Zhang Y, Hill JL, Hartman ZC, Savage MI, Mills GB, Brown PH. Death-associated protein kinase 1 promotes growth of p53-mutant cancers. J Clin Invest 125(7):2707-20, 2015. e-Pub 2015. PMID: 26075823.
- Puvvada N, Rajput S, Kumar BNP, Sarkar S, Konar S, Brunt KR, Rao RR, Mazumdar A, Das SK, Basu R, Fisher PB, Mandal M, Pathak A. Novel ZnO hollow-nanocarriers containing paclitaxel targeting folate-receptors in a malignant pH-microenvironment for effective monitoring and promoting breast tumor regression. Sci Rep 5:11760, 2015. e-Pub 2015. PMID: 26145450.
- Kumar BNP, Puvvada N, Rajput S, Sarkar S, Das SK, Emdad L, Sarkar D, Venkatesan P, Pal I, Dey G, Konar S, Brunt KR, Rao R, Mazumdar A, Kundu SC, Pathak A, Fisher PB, Mandall M. Sequential release of drugs from hollow manganese ferrite nanocarriers for breast cancer therapy. J Mater Chem B 2015(3):90-101, 2014. e-Pub 2014.
- Hartman ZC, Poage GM, den Hollander P, Tsimelzon A, Hill J, Panupinthu N, Zhang Y, Mazumdar A, Hilsenbeck SG, Mills GB, Brown PH. Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the pro-inflammatory cytokines IL-6 and IL-8. Cancer Res 73(11):3470-80, 2013. e-Pub 2013. PMID: 23633491.
- Kumar BN, Rajput S, Dey KK, Parekh A, Das S, Mazumdar A, Mandal M. Celecoxib alleviates tamoxifen-instigated angiogenic effects by ROS-dependent VEGF/VEGFR2 autocrine signaling. BMC Cancer 13:273, 2013. e-Pub 2013. PMID: 23731702.
- Mazumdar A, Medina D, Kittrell FS, Zhang Y, Hill JL, Edwards DE, Bissonnette RP, Brown PH. The combination of tamoxifen and the rexinoid LG100268 prevents ER-positive and ER-negative mammary tumors in p53-null mammary gland mice. Cancer Prev Res (Phila) 5(10):1195-202, 2012. e-Pub 2012. PMID: 22926341.
- Wang C, Uray IP, Mazumdar A, Mayer JA, Brown PH. SLC22A5/OCTN2 expression in breast cancer is induced by estrogen via a novel intronic estrogen-response element (ERE). Breast Cancer Res Treat 134(1):101-15, 2012. e-Pub 2012. PMID: 22212555.
- Wang C, Mayer JA, Mazumdar A, Brown PH. The rearranged during transfection/papillary thyroid carcinoma tyrosine kinase is an estrogen-dependent gene required for the growth of estrogen receptor positive breast cancer cells. Breast Cancer Res Treat 133(2):487-500, 2012. e-Pub 2012. PMID: 21947652.
- Wang C, Mayer JA, Mazumdar A, Fertuck K, Kim H, Brown M, Brown PH. Estrogen Induces c-myc Gene Expression via an Upstream Enhancer Activated by the Estrogen Receptor and the AP-1 Transcription Factor. Mol Endocrinol 25(9):1527-38, 2011. e-Pub 2011. PMID: 21835891.
- Jaganathan SK, Mazumdar A, Mondhe D, Mandal M. Apoptotic effect of eugenol in human colon cancer cell lines. Cell Biol Int 35(6):607-15, 2011. e-Pub 2011. PMID: 21044050.
- Sarkar S, Mazumdar A, Dash R, Sarkar D, Fisher PB, Mandal M. ZD6474 enhances paclitaxel antiproliferative and apoptotic effects in breast carcinoma cells. J Cell Physiol 226(2):375-84, 2011. e-Pub 2011. PMID: 20665703.
- Sarkar S, Mazumdar A, Dash R, Sarkar D, Fisher PB, Mandal M. ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells. Cancer Biol Ther 9(8):592-603, 2010. e-Pub 2010. PMID: 20139705.
- Mazumdar A, Henderson YC, El-Naggar AK, Sen S, Clayman GL. Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma. Head Neck 31((5)):625-34, 2009. e-Pub 2009. PMID: 19107951.
- Robertson FM, Simeone AM, Mazumdar A, Shah AH, McMurray JS, Ghosh S, Cristofanilli M. Molecular and pharmacological blockade of the EP4 receptor selectively inhibits both proliferation and invasion of human inflammatory breast cancer cells. J Exp Ther Oncol 7(4):299-312, 2008. e-Pub 2008. PMID: 19227010.
- Bagheri-Yarmand R, Mazumdar A, Sahin AA, Kumar R. LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system. Int J Cancer 118(11):2703-10, 2006. e-Pub 2006. PMID: 16381000.
- Shellenberger TD, Mazumdar A, Henderson Y, Briggs K, Wang M, Chattopadhyay C, Jayakumar A, Frederick M, Clayman GL. Headpin: a serpin with endogenous and exogenous suppression of angiogenesis. Cancer Res 65(24):11501-9, 2005. e-Pub 2005. PMID: 16357159.
- Mishra SK, Yang Z, Mazumdar A, Talukder AH, Larose L, Kumar R. Metastatic tumor antigen 1 short form (MTA1s) associates with casein kinase I-gamma2, an estrogen-responsive kinase. Oncogene 23(25):4422-9, 2004. e-Pub 2004. PMID: 15077195.
- Mishra SK, Mazumdar A, Vadlamudi RK, Li F, Wang RA, Yu W, Jordan VC, Santen RJ, Kumar R. MICoA, a novel metastasis-associated protein 1 (MTA1) interacting protein coactivator, regulates estrogen receptor-alpha transactivation functions. J Biol Chem 278(21):19209-19, 2003. e-Pub 2003. PMID: 12639951.
- Mazumdar A, Kumar R. Estrogen regulation of Pak1 and FKHR pathways in breast cancer cells. FEBS Lett 535(1-3):6-10, 2003. e-Pub 2003. PMID: 12560069.
- Wang RA, Mazumdar A, Vadlamudi RK, Kumar R. P21-activated kinase-1 phosphorylates and transactivates estrogen receptor-alpha and promotes hyperplasia in mammary epithelium. EMBO J 21(20):5437-47, 2002. e-Pub 2002. PMID: 12374744.
- Mazumdar A, Bandyopadhyay D, Bandyopadhyay U, Banerjee RK. Probing the role of active site histidine residues in the catalytic activity of lacrimal gland peroxidase. Mol Cell Biochem 237(1-2):21-30, 2002. e-Pub 2002. PMID: 12236583.
- Kumar R, Wang RA, Mazumdar A, Talukder AH, Mandal M, Yang Z, Bagheri-Yarmand R, Sahin A, Hortobagyi G, Adam L, Barnes CJ, Vadlamudi RK. A naturally occurring MTA1 variant sequesters oestrogen receptor-alpha in the cytoplasm. Nature 418(6898):654-7, 2002. e-Pub 2002. PMID: 12167865.
- Vadlamudi RK, Wang RA, Mazumdar A, Kim Y, Shin J, Sahin A, Kumar R. Molecular cloning and characterization of PELP1, a novel human coregulator of estrogen receptor alpha. J Biol Chem 276(41):38272-9, 2001. e-Pub 2001. PMID: 11481323.
- Mishra SK, Mandal M, Mazumdar A, Kumar R. Dynamic chromatin remodeling on the HER2 promoter in human breast cancer cells. FEBS Lett 507(1):88-94, 2001. e-Pub 2001. PMID: 11682064.
- Bilanges B, Varrault A, Mazumdar A, Pantaloni C, Hoffmann A, Bockaert J, Spengler D, Journot L. Alternative splicing of the imprinted candidate tumor suppressor gene ZAC regulates its antiproliferative and DNA binding activities. Oncogene 20(10):1246-53, 2001. e-Pub 2001. PMID: 11313869.
- Mazumdar A, Wang RA, Mishra SK, Adam L, Bagheri-Yarmand R, Mandal M, Vadlamudi RK, Kumar R. Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nat Cell Biol 3(1):30-7, 2001. e-Pub 2001. PMID: 11146623.
- Mazumdar A, Adam L, Boyd D, Kumar R. Heregulin regulation of urokinase plasminogen activator and its receptor: human breast epithelial cell invasion. Cancer Res 61(1):400-5, 2001. e-Pub 2001. PMID: 11196194.
- Adam L, Mazumdar A, Sharma T, Jones TR, Kumar R. A three-dimensional and temporo-spatial model to study invasiveness of cancer cells by heregulin and prostaglandin E2. Cancer Res 61(1):81-7, 2001. e-Pub 2001. PMID: 11196203.
- Bilanges B, Varrault A, Basyuk E, Rodriguez C, Mazumdar A, Pantaloni C, Bockaert J, Theillet C, Spengler D, Journot L. Loss of expression of the candidate tumor suppressor gene ZAC in breast cancer cell lines and primary tumors. Oncogene 18(27):3979-88, 1999. e-Pub 1999. PMID: 10435621.
- Mazumdar A, Adak S, Chatterjee R, Banerjee RK. Mechanism-based inactivation of lacrimal-gland peroxidase by phenylhydrazine: a suicidal substrate to probe the active site. Biochem J 324 ( Pt 3):713-9, 1997. e-Pub 1997. PMID: 9210393.
- Adak S, Mazumdar A, Banerjee RK. Low catalytic turnover of horseradish peroxidase in thiocyanate oxidation. Evidence for concurrent inactivation by cyanide generated through one-electron oxidation of thiocyanate. J Biol Chem 272(17):11049-56, 1997. e-Pub 1997. PMID: 9110998.
- Chatterjee R, Bandyopadhyay U, Mazumdar A, Banerjee RK. Lactoperoxidase-catalysed oxidation of indomethacin, a nonsteroidal antiinflammatory drug, through the formation of a free radical. Biochem Pharmacol 52(8):1169-75, 1996. e-Pub 1996. PMID: 8937423.
- Mazumdar A, Chatterjee R, Adak S, Ghosh A, Mondal C, Banerjee RK. Characterization of sheep lacrimal-gland peroxidase and its major physiological electron donor. Biochem J 314 ( Pt 2):413-9, 1996. e-Pub 1996. PMID: 8670050.
- Adak S, Mazumdar A, Banerjee RK. Probing the active site in aromatic donor oxidation in Horseradish peroxidase: Involvement of an arginine and a tyrosine residue in aromatic donor binding. Biochem J 314:985-991, 1996. e-Pub 1996. PMID: 8615798.
- Adak S, Bhattacharyya DK, Mazumdar A, Bandyopadhyay U, Banerjee RK. Concurrent reduction of iodine and oxidation of EDTA at the active site of Horse radish peroxidase: Probing the Iodine binding site by optical difference spectroscopy and steady state kinetic analysis for the formation of active Enzyme -I+ ---EDTA ternary complex and for the iodine reductase activity. Biochemistry 34:12998-13006, 1995. e-Pub 1995.
Review Articles
- Zhao D, Tahaney WM, Mazumdar A, Savage MI, Brown PH. Molecularly targeted therapies for p53-mutant cancers. Cell Mol Life Sci 74(22):4171-4187, 2017. e-Pub 2017. PMID: 28643165.
Patient Reviews
CV information above last modified July 22, 2026